S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
NYSE:ZYME

Zymeworks News Headlines

$18.95
+0.70 (+3.84%)
(As of 12/8/2021 04:00 PM ET)
Add
Compare
Today's Range
$17.71
$19.08
50-Day Range
$18.22
$29.70
52-Week Range
$17.63
$59.03
Volume
1.54 million shs
Average Volume
519,815 shs
Market Capitalization
$882.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89

Media Mentions By Week



Zymeworks Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ZYME
News Sentiment

-0.50

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ZYME Articles
This Week

5

2

ZYME Articles
Average Week

Get Zymeworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Zymeworks (NYSE:ZYME) News Headlines Today

SourceHeadline
nasdaq.com logoAZN's Antibody Authorized For COVID-19, RDUS Shrinks, ZYME On Watch, FDA Panel Snubs RETA - Nasdaq
nasdaq.com - December 9 at 3:59 AM
businesswire.com logoZanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer - Business Wire
businesswire.com - December 8 at 10:20 PM
MarketBeat logoZymeworks (NYSE:ZYME) Reaches New 52-Week Low at $17.63
americanbankingnews.com - December 6 at 2:42 PM
MarketBeat logoZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - December 5 at 4:30 AM
MarketBeat logoZymeworks Inc. (NYSE:ZYME) Expected to Post Quarterly Sales of $11.19 Million
americanbankingnews.com - December 3 at 1:58 AM
businesswire.com logoZymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms - Business Wire
businesswire.com - December 1 at 3:12 PM
nasdaq.com logoAfter Hours Most Active for Nov 24, 2021 : ATUS, EDU, ZNGA, SBGI, DCPH, INTC, BMY, IQ, MSFT, XOM, ZYME, JNPR - Nasdaq
nasdaq.com - November 24 at 5:47 PM
uk.finance.yahoo.com logoInvestors in Zymeworks (NYSE:ZYME) have made a favorable return of 72% over the past three years - Yahoo Finance UK
uk.finance.yahoo.com - November 24 at 7:45 AM
MarketBeat logoZymeworks (NYSE:ZYME) Sets New 1-Year Low at $18.09
americanbankingnews.com - November 23 at 1:04 PM
finance.yahoo.com logoInvestors in Zymeworks (NYSE:ZYME) have made a favorable return of 72% over the past three years
finance.yahoo.com - November 22 at 6:14 PM
MarketBeat logoZymeworks (NYSE:ZYME) Trading 5.2% Higher
americanbankingnews.com - November 22 at 12:44 PM
MarketBeat logoZymeworks Inc. (NYSE:ZYME) Short Interest Down 22.6% in October
americanbankingnews.com - November 20 at 5:18 PM
businesswire.com logoZymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS) - Business Wire
businesswire.com - November 19 at 11:10 PM
finance.yahoo.com logoZymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS) - Yahoo Finance
finance.yahoo.com - November 19 at 1:09 PM
MarketBeat logoZymeworks (NYSE:ZYME) Hits New 1-Year Low at $18.79
americanbankingnews.com - November 16 at 12:28 PM
MarketBeat logoZymeworks (NYSE:ZYME) Rating Reiterated by SVB Leerink
americanbankingnews.com - November 15 at 8:44 AM
finance.yahoo.com logoALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights - Yahoo Finance
finance.yahoo.com - November 11 at 8:22 PM
seekingalpha.com logoZymeworks names Neil Josephson, M.D., CMO - Seeking Alpha
seekingalpha.com - November 11 at 10:21 AM
businesswire.com logoZymeworks Names Neil Josephson, M.D., Chief Medical Officer - Business Wire
businesswire.com - November 9 at 5:00 PM
finance.yahoo.com logoZymeworks Names Neil Josephson, M.D., Chief Medical Officer
finance.yahoo.com - November 9 at 5:00 PM
finance.yahoo.com logoZymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
finance.yahoo.com - November 9 at 11:59 AM
nasdaq.com logoZymeworks Inc. (ZYME) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq
nasdaq.com - November 4 at 2:34 AM
finance.yahoo.com logoZymeworks Reports 2021 Third Quarter Financial Results - Yahoo Finance
finance.yahoo.com - November 3 at 4:33 PM
finance.yahoo.com logoZymeworks Reports 2021 Third Quarter Financial Results
finance.yahoo.com - November 3 at 4:33 PM
finance.yahoo.com logoHedge Funds Are Dumping Zymeworks Inc. (ZYME) - Yahoo Finance
finance.yahoo.com - October 29 at 3:27 PM
nasdaq.com logoWill Zymeworks Inc. (ZYME) Report Negative Q3 Earnings? What You Should Know - Nasdaq
nasdaq.com - October 26 at 9:03 PM
businesswire.com logoZymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers - Business Wire
businesswire.com - October 26 at 10:28 AM
nasdaq.com logoZymeworks (ZYME) Sees Hammer Chart Pattern: Time to Buy? - Nasdaq
nasdaq.com - October 25 at 5:58 PM
finance.yahoo.com logoZymeworks (ZYME) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - October 25 at 7:58 AM
nasdaq.com logoWells Fargo: These 3 Stocks Are Poised to Surge by at Least 40% - Nasdaq
nasdaq.com - October 21 at 3:17 PM
nasdaq.com logoHere's Why Zymeworks Inc. (ZYME) is Poised for a Turnaround After Losing 24.1% in 4 Weeks - Nasdaq
nasdaq.com - October 11 at 2:39 PM
businesswire.com logoZymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors - Business Wire
businesswire.com - October 7 at 10:24 AM
finance.yahoo.com logoZymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors - Yahoo Finance
finance.yahoo.com - October 5 at 11:44 AM
seekingalpha.com logoWarning: ZYME has been downgraded to Very Bearish - Seeking Alpha
seekingalpha.com - September 27 at 6:57 AM
nasdaq.com logoEstimating The Fair Value Of Clean Harbors, Inc. (NYSE:CLH) - Nasdaq
nasdaq.com - September 18 at 1:19 AM
seekingalpha.com logoRecent Zymeworks zanidatamab data could "intensify" sale talk - Dealreporter - Seeking Alpha
seekingalpha.com - September 17 at 8:18 PM
finance.yahoo.com logoWe're Not Worried About Zymeworks' (NYSE:ZYME) Cash Burn
finance.yahoo.com - September 17 at 3:18 PM
benzinga.com logoZymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial - Benzinga
benzinga.com - September 16 at 3:07 PM
businesswire.com logoZymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress - Business Wire
businesswire.com - September 12 at 9:10 PM
theglobeandmail.com logoPfizer to buy Canadian ‘blockbuster’ cancer drug developer Trillium Therapeutics in $2.26-billion deal
theglobeandmail.com - August 25 at 2:19 AM
nasdaq.com logoNew Strong Sell Stocks for August 10th - Nasdaq
nasdaq.com - August 10 at 1:01 PM
finance.yahoo.com logoZymeworks Reports 2021 Second Quarter Financial Results - Yahoo Finance
finance.yahoo.com - August 5 at 10:40 AM
nasdaq.com logoZymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq
nasdaq.com - August 5 at 5:39 AM
seekingalpha.com logoZymeworks EPS misses by $0.02, misses on revenue - Seeking Alpha
seekingalpha.com - August 4 at 10:38 PM
finance.yahoo.com logoZymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
finance.yahoo.com - August 4 at 10:38 PM
finance.yahoo.com logoZymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 4 at 10:38 PM
businesswire.com logoZymeworks Reports 2021 Second Quarter Financial Results - Business Wire
businesswire.com - August 4 at 5:37 PM
finance.yahoo.com logoZymeworks Reports 2021 Second Quarter Financial Results
finance.yahoo.com - August 4 at 5:37 PM
benzinga.com logoZymeworks Reports Milestone Payment As J&J's Janssen Achieves First Patient Dosed For Bispecific Antibody Utilizing Zymeworks' Azymetric, EFECT Therapeutic Platforms - Benzinga
benzinga.com - August 4 at 7:37 AM
benzinga.com logoUPDATE: Zymeworks Received Upfront Payment Of $50M, Is Eligible To Potentially Receive Up To $282M In Development, Up To $1.12B In Commercial Milestone Payments - Benzinga
benzinga.com - August 3 at 9:38 AM
Get Zymeworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/9/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.